Header

UZH-Logo

Maintenance Infos

Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model


Weber, B; Dijkman, P E; Scherman, J; Sanders, B; Emmert, M Y; Grünenfelder, J; Verbeek, R; Bracher, M; Black, M; Franz, T; Kortsmit, J; Modregger, P; Peter, S; Stampanoni, M; Robert, J; Kehl, D; van Doeselaar, M; Schweiger, M; Brokopp, C E; Wälchli, T; Falk, V; Zilla, P; Driessen-Mol, A; Baaijens, F P; Hoerstrup, S P (2013). Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials, 34(30):7269-7280.

Abstract

Heart valve tissue engineering based on decellularized xenogenic or allogenic starter matrices has shown promising first clinical results. However, the availability of healthy homologous donor valves is limited and xenogenic materials are associated with infectious and immunologic risks. To address such limitations, biodegradable synthetic materials have been successfully used for the creation of living autologous tissue-engineered heart valves (TEHVs) in vitro. Since these classical tissue engineering technologies necessitate substantial infrastructure and logistics, we recently introduced decellularized TEHVs (dTEHVs), based on biodegradable synthetic materials and vascular-derived cells, and successfully created a potential off-the-shelf starter matrix for guided tissue regeneration. Here, we investigate the host repopulation capacity of such dTEHVs in a non-human primate model with up to 8 weeks follow-up. After minimally invasive delivery into the orthotopic pulmonary position, dTEHVs revealed mobile and thin leaflets after 8 weeks of follow-up. Furthermore, mild-moderate valvular insufficiency and relative leaflet shortening were detected. However, in comparison to the decellularized human native heart valve control - representing currently used homografts - dTEHVs showed remarkable rapid cellular repopulation. Given this substantial in situ remodeling capacity, these results suggest that human cell-derived bioengineered decellularized materials represent a promising and clinically relevant starter matrix for heart valve tissue engineering. These biomaterials may ultimately overcome the limitations of currently used valve replacements by providing homologous, non-immunogenic, off-the-shelf replacement constructs.

Abstract

Heart valve tissue engineering based on decellularized xenogenic or allogenic starter matrices has shown promising first clinical results. However, the availability of healthy homologous donor valves is limited and xenogenic materials are associated with infectious and immunologic risks. To address such limitations, biodegradable synthetic materials have been successfully used for the creation of living autologous tissue-engineered heart valves (TEHVs) in vitro. Since these classical tissue engineering technologies necessitate substantial infrastructure and logistics, we recently introduced decellularized TEHVs (dTEHVs), based on biodegradable synthetic materials and vascular-derived cells, and successfully created a potential off-the-shelf starter matrix for guided tissue regeneration. Here, we investigate the host repopulation capacity of such dTEHVs in a non-human primate model with up to 8 weeks follow-up. After minimally invasive delivery into the orthotopic pulmonary position, dTEHVs revealed mobile and thin leaflets after 8 weeks of follow-up. Furthermore, mild-moderate valvular insufficiency and relative leaflet shortening were detected. However, in comparison to the decellularized human native heart valve control - representing currently used homografts - dTEHVs showed remarkable rapid cellular repopulation. Given this substantial in situ remodeling capacity, these results suggest that human cell-derived bioengineered decellularized materials represent a promising and clinically relevant starter matrix for heart valve tissue engineering. These biomaterials may ultimately overcome the limitations of currently used valve replacements by providing homologous, non-immunogenic, off-the-shelf replacement constructs.

Statistics

Citations

Dimensions.ai Metrics
83 citations in Web of Science®
86 citations in Scopus®
101 citations in Microsoft Academic
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiovascular Surgery
04 Faculty of Medicine > University Hospital Zurich > Division of Surgical Research
04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurosurgery
04 Faculty of Medicine > University Children's Hospital Zurich > Clinic for Surgery
04 Faculty of Medicine > Institute of Biomedical Engineering
Dewey Decimal Classification:170 Ethics
610 Medicine & health
Language:English
Date:October 2013
Deposited On:05 Sep 2013 12:29
Last Modified:18 Aug 2018 11:04
Publisher:Elsevier
ISSN:0142-9612
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/j.biomaterials.2013.04.059
PubMed ID:23810254
Project Information:
  • : FunderSNSF
  • : Grant ID33CM30_124090
  • : Project TitleAdvanced Cell Therapies for Cardiac Repair-SPUM
  • : FunderFP7
  • : Grant ID242008
  • : Project TitleLIFEVALVE - Living autologous heart valves for minimally invasive implantable procedures

Download

Full text not available from this repository.
View at publisher

Get full-text in a library